<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149761">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02022488</url>
  </required_header>
  <id_info>
    <org_study_id>162</org_study_id>
    <nct_id>NCT02022488</nct_id>
  </id_info>
  <brief_title>Sevoflurane Induced Emergence Agitation</brief_title>
  <official_title>Prevention of Emergence Agitation in Children After Sevoflurane Anesthesia With Ketamine-midazolam Combination: A Prospective Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yeditepe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yeditepe University Hospital</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators evaluated the effect of intranasal ketamine or alfentanil addition to oral
      midazolam for prevention of emergence agitation.Seventy-eight, 1-8 year-old children,
      undergoing urological surgery with sevoflurane anesthesia was included in the study. All the
      children received oral midazolam 0.5 mg/kg 40 minutes before anesthesia induction then
      enrolled to one of the study groups, randomly. Ketamine group (Group MK; n=26) patients were
      given 2mg/kg intranasal ketamine whereas, alfentanil group (Group MA; n=25) were given
      10microgram/kg intranasal alfentanil 8-10 min before the induction of anesthesia. Saline
      group (Group MS; n=27) received intranasal isotonic saline.Parental separation, mask
      acceptance were evaluated with a 4- point scale. Emergence agitation was evaluated with
      Pediatric Anesthesia Emergence Delirium score.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Pediatric Anesthesia Emergence Delirium (PAED) score</measure>
    <time_frame>7 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Emergence agitation was evaluated using the Pediatric Anesthesia Emergence Delirium (PAED) score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parental separation score</measure>
    <time_frame>7 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Parental separation were evaluated with a 4- point scale in the preoperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mask acceptance</measure>
    <time_frame>7 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The ease of mask acceptance were evaluated with a 4- point scale in the preoperative period</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Emergence Agitation</condition>
  <arm_group>
    <arm_group_label>midazolam and alfentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam 0.5mg/kg (oral) Alfentanil 10 microgram/kg (oral)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>midazolam and ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam 0.5mg/kg (oral) Ketamine 2mg/kg (intranasal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>midazolam</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Midazolam 0.5mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
    <description>Group M</description>
    <arm_group_label>midazolam and alfentanil</arm_group_label>
    <arm_group_label>midazolam and ketamine</arm_group_label>
    <arm_group_label>midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alfentanil</intervention_name>
    <description>Group MA</description>
    <arm_group_label>midazolam and alfentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketamine</intervention_name>
    <description>Group MK</description>
    <arm_group_label>midazolam and ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1- 8 years

          -  American Society of Anesthesiologist (ASA) I-II,

          -  Patients undergoing procedures below the umbilicus

        Exclusion Criteria:

          -  cardiac diseases

          -  pulmonary diseases

          -  hepatic diseases

          -  renal diseases

          -  psychological or emotional disorders
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yeditepe University Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34752</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 26, 2013</lastchanged_date>
  <firstreceived_date>December 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yeditepe University Hospital</investigator_affiliation>
    <investigator_full_name>Sevgi Bilgen</investigator_full_name>
    <investigator_title>Yeditepe University</investigator_title>
  </responsible_party>
  <keyword>Child</keyword>
  <keyword>Sevoflurane</keyword>
  <keyword>Emergence delirium</keyword>
  <keyword>General anesthesia</keyword>
  <keyword>Premedication.</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alfentanil</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
